| Srinivas M Ammisetty, MD | |
|
9350 Us Hwy 23 South, Suite 104, Stanville, KY 41659 | |
| (606) 478-1005 | |
| (606) 478-8687 |
| Full Name | Srinivas M Ammisetty |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 38 Years |
| Location | 9350 Us Hwy 23 South, Stanville, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689758799 | NPI | - | NPPES |
| 65943516 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 35594 (Kentucky) | Primary |
| 207RS0012X | Internal Medicine - Sleep Medicine | 35594 (Kentucky) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Pikeville Medical Center | Pikeville, KY | Hospital |
| Arh Our Lady Of The Way | Martin, KY | Hospital |
| Tug Valley Arh Regional Medical Center | South williamson, KY | Hospital |
| Paul B Hall Regional Medical Center | Paintsville, KY | Hospital |
| Entity Name | East Ky Pulmonary & Sleep Disorder Ctr. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013063106 PECOS PAC ID: 3779512447 Enrollment ID: O20050812000078 |
News Archive
David H. Fater, CEO of Vicor Technologies, Inc., today announced the initial results of a study designed to analyze data from the Merte Subita en Insufficiencia Cardiaca Trial using its PD2i- algorithm and software. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i- nonlinear algorithm and software.
Italian and German scientists have designed peptides to target the protein-protein interface of a key enzyme in DNA synthesis crucial for cancer growth. The peptides act by a novel inhibitory mechanism and curb cancer cell growth in drug resistant ovarian cancer cells.
Roche announced today it has licensed its P2X3 receptor program aimed at developing first-in-class treatments for chronic pain to Afferent Pharmaceuticals. Afferent was co-founded by Anthony Ford, Ph.D., Pappas Ventures, and Third Rock Ventures, and is focused on developing compounds that treat chronic pain by targeting a novel biological pathway.
Scientists at the Medical College of Georgia at Augusta University are looking at new treatment targets for the retinal damage that often accompanies diseases like diabetes, glaucoma and hypertension.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Srinivas M Ammisetty, MD 9350 Us Hwy 23 South, P O Box 70, Stanville, KY 41659 Ph: (606) 478-1005 | Srinivas M Ammisetty, MD 9350 Us Hwy 23 South, Suite 104, Stanville, KY 41659 Ph: (606) 478-1005 |
News Archive
David H. Fater, CEO of Vicor Technologies, Inc., today announced the initial results of a study designed to analyze data from the Merte Subita en Insufficiencia Cardiaca Trial using its PD2i- algorithm and software. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i- nonlinear algorithm and software.
Italian and German scientists have designed peptides to target the protein-protein interface of a key enzyme in DNA synthesis crucial for cancer growth. The peptides act by a novel inhibitory mechanism and curb cancer cell growth in drug resistant ovarian cancer cells.
Roche announced today it has licensed its P2X3 receptor program aimed at developing first-in-class treatments for chronic pain to Afferent Pharmaceuticals. Afferent was co-founded by Anthony Ford, Ph.D., Pappas Ventures, and Third Rock Ventures, and is focused on developing compounds that treat chronic pain by targeting a novel biological pathway.
Scientists at the Medical College of Georgia at Augusta University are looking at new treatment targets for the retinal damage that often accompanies diseases like diabetes, glaucoma and hypertension.
› Verified 7 days ago